Jonathan Rigby is the founder of Revolo Biotherapeutics. Revolo Biotherapeutics has raised $53M in total funding. Latest round: Series B.
Jonathan Rigby is the Group CEO of Revolo Biotherapeutics, a clinical-stage biotech company focused on resetting the immune system to treat autoimmune and allergic diseases. He was the first employee in the U.S. for the company, led a $53.4 million Series B financing round, and expanded the U.S. presence by hiring expert executives.
Full founder directory · Investor directory · Company funding database · Fundraising library